VITALITY BIOPHARMA, INC (OTCMKTS:VBIO) Files An 8-K Financial Statements and Exhibits
Item 9.01 of the October 8-K and provides the historical financial information required to Item 9.01(a) of Form 8-K and the pro forma financial information required to Item 9.01(b) of Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired
The following financial statements of The Control Center, Inc. and related documents are included as Exhibit 99.1 hereto and incorporated herein by reference:
● The audited financial statements The Control Center, Inc. as of September 30, 2018 and 2017 and for the years then ended.
(b) Pro Forma Financial Information
The following unaudited pro forma combined condensed financial statements required to Item 9.01(b) of Form 8-K are included as Exhibit 99.2 hereto and are incorporated herein by reference:
● Unaudited Pro Forma Condensed Consolidated Balance Sheet of Vitality Biopharma, Inc. and The Control Center, as of September 30, 2018, and Unaudited Pro Forma Condensed Consolidated Statements of Operations of Vitality Biopharma, Inc. and The Control Center, Inc. for the year ended March 31, 2018 and for the six-month period ended September 30, 2018.
(d) Exhibits
| Exhibit No. | Description |
| 23.1 | Consent of Independent Registered Public Accounting Firm* |
| 99.1 | Audited financial statements of The Control Center, Inc. as of September 30, 2018 and 2017 and for the years then ended and accompanying notes * |
| 99.2 | Unaudited Pro Forma Condensed Consolidated Balance Sheet of Vitality Biopharma, Inc. and The Control Center, as of September 30, 2018, and Unaudited Pro Forma Combined Condensed Statements of Operations of Vitality Biopharma, Inc. and The Control Center, Inc.for the year ended March 31, 2018 and for the six-month period ended September 30, 2018 * |
*Filed herewith
Vitality Biopharma, Inc. Exhibit
EX-23.1 2 ex23-1.htm Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors Vitality Biopharma,…
To view the full exhibit click here
About VITALITY BIOPHARMA, INC (OTCMKTS:VBIO)
Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The Company unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its product pipeline includes cannabosides, VITA-100 and VITA-210. Cannabosides are cannabinoid glycoside prodrugs. VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for treatment of inflammatory bowel disease, epilepsy, schizophrenia, and other disorders. VITA-210 is a cannabinoid glycoside prodrug being developed primarily for treatment of pain and muscle spasticity in multiple sclerosis and in rare white matter disorders. The Company’s facilities include laboratories and a manufacturing suite for good manufacturing practices (GMPs) production, which will be used for pharmaceutical-grade production of products to be tested in clinical trials.